BVAXF
BioVaxys Technology Corp.
Set alert
0.09 USD 0.00 0.00%
0.0677 Day range 0.0677
0.0102 52-week range 0.208
- YTD
- -46.84%
- 1 year
- -50.25%
- Open
- 0.0677
- Prev close
- 0.09
- Mkt cap
- 3.66M
- Vol
- 150
- Avg vol
- 21.74K
- EPS
- -0.15
- P/E
- 0.00
More statistics
- Low
- 0.0677
- High
- 0.0677
News
- BioVaxys Technology Corp. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
- BioVaxys Presents Further Validation of the Robust Immune Response from a Combination of MVP-S with Checkpoint Inhibitors and Low-Dose Cyclophosphamide in Ovarian Cancer
- BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
- BioVaxys Announces Phase I/II PESCO Trial Abstract Accepted for Presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
- BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
- BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
- BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
- BioVaxys Announces Application for Management Cease Trade Order
- BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer
- BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC)
Your note
Sign in to keep a note on BVAXF — it syncs with the Stock Master app.